Clinicopathologic and Ancillary Testing of Primary Clear Cell Carcinoma of the Cervix

Recruiting

• Conditions: Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type
• Interventions: Other: Electronic Health Record Review; Other: Laboratory Biomarker Analysis

• Registration Number: NCT05046080
• Lead Sponsor: M.D. Anderson Cancer Center

Brief Summary

This study aims to provide a comprehensive report on clinicopathologic features, immunohistochemical/biomarker testing and molecular profile of cervical clear cell carcinoma. This study may help researchers learn more about the molecular profile of cervical clear cell carcinoma.

Detailed Description

PRIMARY OBJECTIVE:

I. To perform a retrospective clinicopathologic study on patients diagnosed and treated for clear cell carcinoma of the cervix at M D Anderson Cancer Center (MDACC) and to delineate the immunohistochemical and molecular profile of these cases.

OUTLINE:

Patients' medical records are reviewed retrospectively, and archival tumor tissue analyzed by immunohistochemistry and next generation sequencing.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2021-08-06
• Study First Submitted: 2021-08-25
• Study First Submitted QC: 2021-09-13
• Study First Posted: 2021-09-16
• Status Verified: 2024-08
• Last Update Submitted: 2024-08-27
• Last Update Posted: 2024-08-28
• Primary Completion: 2026-09-29
• Study Completion: 2026-09-29

Recruitment & Eligibility

• Status: RECRUITING
• Sex: Female
• Target Recruitment: 70

Inclusion Criteria

• Patients diagnosed with clear cell carcinoma of the cervix at MDACC

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Observational (medical record review)	Electronic Health Record Review	Patients' medical records are reviewed retrospectively, and archival tumor tissue analyzed by immunohistochemistry and next generation sequencing.
Observational (medical record review)	Laboratory Biomarker Analysis	Patients' medical records are reviewed retrospectively, and archival tumor tissue analyzed by immunohistochemistry and next generation sequencing.

Primary Outcome Measures

Name	Time	Method
Clinicopathologic study on patients diagnosed and treated for clear cell carcinoma of the cervix	through study completion, an average of 1 year

Trial Locations

Locations (1)

M D Anderson Cancer Center; 🇺🇸 Houston, Texas, United States